In hepatocellular carcinoma (HCC), Huang et al. reported that sorafenib induced MET formation via the Rho GDP dissociation inhibitor gamma (ARHGDIG)/IL-4/PADI4 axis, which led to the inhibition of ferroptosis and the development of sorafenib resistance [50]. This evidence concerns the gene PADI4 and hepatocellular carcinoma.